Copertina

Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Andrew C. Charles, Kathleen B. Digre, Peter J. Goadsby, Matthew S. Robbins, Andrew Hershey
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Headache: The Journal of Head and Face Pain
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society
di: Todd J. Schwedt, et al.
Pubblicazione: (2025)

The cortical spreading depression/migraine aura hypothesis – Finally some definitive evidence
di: Andrew C. Charles, et al.
Pubblicazione: (2025)

A critical appraisal of the International Classification of Headache Disorders migraine diagnostic criteria based on a retrospective multicenter cross‐sectional headache registry study in youth
di: Carlyn Patterson Gentile, et al.
Pubblicazione: (2024)

Navigating the patient journey in migraine prevention: An American Migraine Foundation position paper
di: Lawrence C. Newman, et al.
Pubblicazione: (2025)

Migraine, idiopathic intracranial hypertension, and calcitonin gene‐related peptide antibodies
di: Irina Krikova, et al.
Pubblicazione: (2024)

Evaluating dual calcitonin gene‐related peptide antagonists for chronic migraine prevention
di: Kara S. Graves, et al.
Pubblicazione: (2026)

Response to: Reassessing pediatric migraine disability: Toward an updated assessment tool in the era of novel therapeutics
di: Christina Murphy, et al.
Pubblicazione: (2025)

2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
di: Jennifer Robblee, et al.
Pubblicazione: (2025)

The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
di: Jennifer Robblee, et al.
Pubblicazione: (2024)

Flexible modeling of headache frequency fluctuations in migraine with hidden Markov models
di: Gina M. Dumkrieger, et al.
Pubblicazione: (2024)

Genetic migraine disorders and the response to calcitonin gene‐related peptide antagonist treatment
di: Andrea M. Kuczynski, et al.
Pubblicazione: (2025)

Integrating gepants into clinical practice for the acute treatment of migraine
di: Richard B. Lipton, et al.
Pubblicazione: (2026)

The safety and efficacy of onabotulinumtoxinA injections for children and adolescents with chronic migraine: A systematic review and meta‐analysis
di: Rebecca Lindsay, et al.
Pubblicazione: (2024)

Youth with high‐frequency headaches due to migraine are more vulnerable to non‐cephalic pain complaints
di: Brooke L. Reidy, et al.
Pubblicazione: (2025)

Evaluating associations of migraine‐related vertigo
di: Nazia Karsan, et al.
Pubblicazione: (2025)

Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
di: Samuel K. Peasah, et al.
Pubblicazione: (2024)

Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
di: Michael L. Garelja, et al.
Pubblicazione: (2025)

Clinical factors associated with day‐to‐day peak pain severity in individuals with chronic migraine: A cohort study using daily prospective diary data
di: Marina Vives‐Mestres, et al.
Pubblicazione: (2024)

Response to: Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays
di: Alicia Alpuente, et al.
Pubblicazione: (2026)

Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
di: Anna de Dios, et al.
Pubblicazione: (2024)

Headache‐related disability as a function of migraine aura: A daily diary study
di: Delora E. Denney, et al.
Pubblicazione: (2024)

Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
di: Alba López‐Bravo, et al.
Pubblicazione: (2025)

Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment
di: Joanna K. Bougie, et al.
Pubblicazione: (2024)

Response to Letter to the Editor regarding “Calcitonin gene‐related peptide and headache: Comparison of two commonly used assay kits highlights the perils of measuring neuropeptides with enzyme‐linked immunosorbent assays”
di: Michael L. Garelja, et al.
Pubblicazione: (2026)

Treatment of abdominal migraine in an 8‐year‐old child with calcitonin gene‐related peptide receptor antagonist: A case report
di: Yunzhu Tang, et al.
Pubblicazione: (2025)

Letter to the Editor regarding “Persistence, effectiveness, and tolerability of anti‐calcitonin gene‐related peptide monoclonal antibodies in patients with chronic migraine”
di: Joaquín Borrás‐Blasco, et al.
Pubblicazione: (2025)

Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double‐dummy pilot trial
di: Serena Laura Orr, et al.
Pubblicazione: (2024)

The American Headache Society First Contact—Headache in Primary Care program: Current metrics, knowledge assessments, and direction for future initiatives
di: Mia T. Minen, et al.
Pubblicazione: (2024)

Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists
di: Zoe Tasma, et al.
Pubblicazione: (2025)

Amplifying and ameliorating light avoidance in mice with photoreceptor targeting and calcitonin gene‐related peptide sensitization
di: Eric A. Kaiser, et al.
Pubblicazione: (2025)

The critical role of neuroimaging in hemicrania continua: A systematic review and case series
di: Hasna Yildiz Goksel, et al.
Pubblicazione: (2024)

A retrospective analysis of the use of candesartan for migraine prevention in adolescents
di: Irene Patniyot, et al.
Pubblicazione: (2024)

Cluster Analysis of Migraine‐associated Symptoms (CAMS) in youth: A retrospective cross‐sectional multicenter study
di: Carlyn Patterson Gentile, et al.
Pubblicazione: (2024)

The pathogenic role of calcitonin gene‐related peptide and predictors of new‐onset migraine and long‐term outcomes after transcatheter atrial septal defect closure
di: Tzu‐Hsuan Su, et al.
Pubblicazione: (2024)

Differences in circulating alpha‐calcitonin gene–related peptide levels in inflammatory bowel disease and its relation to migraine comorbidity: A cross‐sectional study
di: Marta Pascual‐Mato, et al.
Pubblicazione: (2024)

Bridging old and new: The 2026 American Headache Society Annual Scientific Meeting
di: Mark J. Burish, et al.
Pubblicazione: (2026)

Reliability, validity, and responsiveness of the Arabic version of HIT ‐6 questionnaire in patients with migraine indicated for preventive therapy: A multi‐center study
di: Mona Hussein, et al.
Pubblicazione: (2024)

Effectiveness and acceptability of oral migraine preventives: A prospective, observational study
di: Hedda S. Riise, et al.
Pubblicazione: (2026)

Behavioral interventions for migraine prevention: A systematic review and meta‐analysis
di: Jonathan R. Treadwell, et al.
Pubblicazione: (2025)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
di: Chia‐Chun Chiang, et al.
Pubblicazione: (2024)